SPOTLIGHT -
The Week in Review: November 28-December 2
From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.
Reef Madness: Digging up the Dirt on an Australian Myth
“Hunter’s book is excellently written and highly recommended for readers who want to understand the enormous power of myth in the Australian identity.”
Hooked on Hype? A Critical Examination of Recent Anti-Antidepressant Reporting
Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.
First TAAR1 Agonist Studied as Adjunctive Therapy for MDD
The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.
Shining Light on Gaslighting
Merriam-Webster’s Word of 2022: gaslighting.
Manatees and Mental Health Months
Perhaps we should try to act more like manatees…
Don’t Grow Old, Grow Bold Together
Don’t grow old in your relationship, grow bold.
Formic Acid as a Urinary Biomarker for Early-Stage Alzheimer Disease
New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.
Phase 1 Study of Apimostinel for Depression Doses First Participants
The drug is in development for the treatment of acute depressive disorders and depression with suicidality.
Phase 3 Trial of Dexmedetomidine for Bipolar I or II, Schizophrenia Doses First Participants
The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.
From the Pages of Psychiatric Times: November 2022
The experts weighed in on a wide variety of psychiatric issues for the November 2022 issue of Psychiatric Times.
Thinking Beyond the Guidelines: Evidence-Based Novel Therapies for Bipolar Depression
In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.
Be a Light
Acknowledging the impact of holidays on others, and what to do when things get dark.
Covering the Basics: LGBTQ+ Terminology
Do you know these terms?
Affirming Evidence-Based Care for Young Patients Who Are Transgender or Gender Diverse
Psychiatrists are in a unique position to empower their patients by recognizing and addressing key issues surrounding gender and sexuality.
The Health Care Professional Ethical Choice: Ukraine, Iran, and Whether or When to Risk and Resist
What would it take for psychiatrists and other physicians in the United States to collectively resist risks to the public’s health and mental health?
Ukraine Now: Never so Difficult, Never so Easy
An update from Ukraine.
The Importance of Avoiding Implicit Bias in Advocating for Patients
"Our own implicit biases come into play at times whether we like it or not, especially when it comes to frequently controversial medications."
To Address Climate Change, This Psychiatrist Goes Where No One Has Gone Before
Psychiatry and inner space—closer than you think.
What’s Your Favorite Holiday Activity?
Tell us about your holiday traditions for a chance to be featured in our Holiday Traditions series.
The Week in Review: November 21-25
From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.
Leveraging GAT to Address Sleep Burden in Youth
New research explores the impact of GAT on TGNC youth.
Cheerful and Tearful Over Thanksgiving Weekend
The two sides of the Thanksgiving coin… what are they and what do they mean?
Tales From the Clinic: Leading by Case Example
Have you missed the latest episodes of the series Tales From the Clinic: The Art of Psychiatry?
Broaching the Topic of Gratitude
How can you foster gratitude in your patients?
Psychiatrist Humility and Patient Empowerment
“Both doctors and patients know best.”
Concurrent Treatment With SRIs and Anticoagulants: Minimizing the Hemorrhagic Hazard
An important adverse effect of SRIs: their association with increased bleeding.
Senators Introduce New Bill to Promote Research and Access to MDMA, Psilocybin
A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.
Thanksgivukkah
Combining Thanksgiving, Hanukkah, and December birthday celebrations for the ultimate unique family dinner.
The Benefits and Limitations of Resilience
While resilience is beneficial to mental health, we need to reduce the reasons individuals require resilience.
